MX2023006720A - Tratamiento con ciclobenzaprina para fibromialgia. - Google Patents

Tratamiento con ciclobenzaprina para fibromialgia.

Info

Publication number
MX2023006720A
MX2023006720A MX2023006720A MX2023006720A MX2023006720A MX 2023006720 A MX2023006720 A MX 2023006720A MX 2023006720 A MX2023006720 A MX 2023006720A MX 2023006720 A MX2023006720 A MX 2023006720A MX 2023006720 A MX2023006720 A MX 2023006720A
Authority
MX
Mexico
Prior art keywords
fibromyalgia
dosage units
cyclobenzaprine
cyclobenzaprine hcl
treatment
Prior art date
Application number
MX2023006720A
Other languages
English (en)
Spanish (es)
Inventor
Seth Lederman
Gregory M Sullivan
Original Assignee
TONIX Pharmaceuticals Holding Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TONIX Pharmaceuticals Holding Corp filed Critical TONIX Pharmaceuticals Holding Corp
Publication of MX2023006720A publication Critical patent/MX2023006720A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023006720A 2020-12-07 2021-12-07 Tratamiento con ciclobenzaprina para fibromialgia. MX2023006720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063122469P 2020-12-07 2020-12-07
PCT/US2021/062244 WO2022125572A1 (en) 2020-12-07 2021-12-07 Cyclobenzaprine treatment for fibromyalgia

Publications (1)

Publication Number Publication Date
MX2023006720A true MX2023006720A (es) 2023-08-18

Family

ID=79686930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006720A MX2023006720A (es) 2020-12-07 2021-12-07 Tratamiento con ciclobenzaprina para fibromialgia.

Country Status (9)

Country Link
US (2) US20240024256A1 (https=)
EP (1) EP4255407A1 (https=)
JP (1) JP2023554692A (https=)
CN (1) CN116940340A (https=)
AU (1) AU2021396509A1 (https=)
CA (1) CA3204202A1 (https=)
IL (1) IL303497A (https=)
MX (1) MX2023006720A (https=)
WO (1) WO2022125572A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3260042A1 (en) * 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF A (SARS)-COV-2 (PASC) INFECTION
WO2025137348A1 (en) * 2023-12-19 2025-06-26 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63822B1 (sr) 2012-06-15 2023-01-31 Tonix Pharma Holdings Ltd Kompozicije i postupci za transmukoznu apsorpciju
SMT202400324T1 (it) 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
MY186047A (en) * 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
US20220117915A1 (en) * 2018-08-20 2022-04-21 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Also Published As

Publication number Publication date
AU2021396509A1 (en) 2023-06-29
WO2022125572A1 (en) 2022-06-16
CN116940340A (zh) 2023-10-24
EP4255407A1 (en) 2023-10-11
US20240024256A1 (en) 2024-01-25
JP2023554692A (ja) 2023-12-28
CA3204202A1 (en) 2022-06-16
IL303497A (en) 2023-08-01
US20260108477A1 (en) 2026-04-23
AU2021396509A9 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
Vuagnat et al. Shoulder pain in hemiplegia revisited: contribution of functional electrical stimulation and other therapies
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
CO2018006358A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
NZ767378A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
MY199903A (en) Combination therapy with controlled-release cnp agonists
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2023006720A (es) Tratamiento con ciclobenzaprina para fibromialgia.
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
Moghadam et al. The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
Blok et al. Intravenous acetaminophen does not have an opioid sparing effect in Emergency Department patients with painful conditions
MX2025000142A (es) Tratamiento con ciclobenzaprina para las secuelas postagudas de la infección por (sars)-cov-2 (pasc)
Massey Reduction of fibromyalgia symptoms through intravenous nutrient therapy: results of a pilot clinical trial
Kilic Melatonin for chronic back pain (the MOCHA trial): A study protocol for a randomized, double blind, placebo-contolled trial
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
SA522432821B1 (ar) توليفة من ميرتازابين وتيزانيدين للاستخدام في اضطرابات الألم
MX2024002602A (es) Métodos para prevenir y tratar el dolor y síntomas asociados.
MX2023003540A (es) Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.
Jensen et al. Onset of treatment response to a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia